EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Self-adjuvanting α-helical polypeptide simultaneously delivers neoantigen mRNAs and activates dendritic cells to eradicate tumors

Joonsu Han iD, Jiadiao Zhou iD, Abhisek Dwivedy, Tianrui Xue, Rimsha Bhatta, Yusheng Liu, Daniel Nguyen, Yang Bo iD, Yueji Wang, Xin Wang iD, Meng Xu iD, Matthew Berry und 7 weitere

Proceedings of the National Academy of Sciences · 21.04.2026 · 123 (16)

DOI: 10.1073/pnas.2504976123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 15.04.2026. Verfasst von Joonsu Han und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Materials Science and Engineering, University of Illinois at Urbana-Champaign, Urbana, IL 61801. Hauptthemen laut MEDLINE: Dendritic Cells, Peptides, Cancer Vaccines, RNA, Messenger. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: DOD | AF | AMC | AFRL | Air Force Office of Scientific Research (AFOSR), Sontag Foundation (The Sontag Foundation), NSF | MPS | Division of Materials Research (DMR).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

mRNA-based vaccines have demonstrated tremendous success during the era of COVID-19, but its therapeutic potential for treating cancer, especially poorly immunogenic solid tumors, remains largely underachieved. Herein, we report a class of self-adjuvanting α-helical polypeptides that can dramatically improve the antitumor efficacy of tumor neoantigen-encoding mRNAs. The α-helical polypeptides can facilitate the intracellular delivery of mRNAs into dendritic cells (DCs), simultaneously activate DCs by regulating NF-κB and IRF pathways, and improve the ability of dendritic cells to process and present mRNA-encoded neoantigens. Molecular docking and simulation results also confirm the stable complexation between mRNA and α-helical polypeptides. The conceived polyplex, upon subcutaneous administration, can migrate to the draining lymph nodes and transfect and activate DCs in the lymph nodes, resulting in superior neoantigen-specific cytotoxic T lymphocyte response in vivo. Compared to conventional lipoplexes or SM102 lipid nanoparticle-based mRNA vaccines that yield 0% tumor-free survival, the polyplex yields 83.3% and 33.3% tumor-free survival against E.G7-OVA lymphoma and 4T1 triple negative breast cancer, respectively, among the best antitumor efficacy reported to date for mRNA cancer vaccines. The polyplex also reprograms the immunosuppressive tumor microenvironment, by stimulating and enriching DCs, M1-phenotype CD86 + macrophages, and CD8 + T cells in the tumors. We also observed the upregulated expression of Programmed Death-1 (PD-1) by intratumoral CD8 + T cells and PD-L1 by 4T1 tumor cells after polyplex treatment and further demonstrated the synergistic effect between polyplex vaccine and anti-PD-1 therapy. Our polyplex system provides a facile and generalizable approach to developing robust mRNA-based cancer vaccines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dendritic CellsPeptidesCancer VaccinesRNA, MessengerAntigens, NeoplasmAdjuvants, ImmunologicAnimalsMiceFemaleHumansCell Line, TumorMice, Inbred C57BLmRNA VaccinesT-Lymphocytes, CytotoxicNanovaccines

Stichwörter der Autor:innen

adjuvantcancerimmunotherapymRNA vaccinepolypeptide

Substanzen

PeptidesCancer VaccinesRNA, MessengerAntigens, NeoplasmAdjuvants, ImmunologicmRNA VaccinesNanovaccines

Autor:innen und Institutionen

  • Department of Materials Science and Engineering, University of Illinois at Urbana-Champaign, Urbana, IL 61801.
  • Department of Bioengineering, University of Illinois at Urbana-Champaign, Urbana, IL 61801.
  • Department of Veterinary Clinical Medicine, University of Illinois at Urbana-Champaign, Urbana, IL 61801.
  • Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142.
  • Cancer Center at Illinois, Urbana, IL 61801.
  • Carle College of Medicine, University of Illinois at Urbana-Champaign, Urbana, IL 61801.

ORCID-Profile: Joonsu Han, Jiadiao Zhou, Yang Bo, Xin Wang, Meng Xu, Joseph Irudayaraj, Jian Liu, Qian Chen, Shuming Nie, Xing Wang, Hua Wang

Förderung

  • DOD | AF | AMC | AFRL | Air Force Office of Scientific Research (AFOSR)
  • Sontag Foundation (The Sontag Foundation)
  • NSF | MPS | Division of Materials Research (DMR)
  • American Cancer Society (ACS)
  • HHS | NIH | National Cancer Institute (NCI)
  • NCI NIH HHS

Zitieren

APA

Han, J., Zhou, J., Dwivedy, A., Xue, T., Bhatta, R., Liu, Y., Nguyen, D., Bo, Y., Wang, Y., Wang, X., Xu, M., Berry, M., Bailey, K., Irudayaraj, J., Liu, J., Chen, Q., Nie, S., Wang, X., & Wang, H. (2026). Self-adjuvanting α-helical polypeptide simultaneously delivers neoantigen mRNAs and activates dendritic cells to eradicate tumors. Proceedings of the National Academy of Sciences, 123(16). https://doi.org/10.1073/pnas.2504976123

Vancouver

Han J, Zhou J, Dwivedy A, Xue T, Bhatta R, Liu Y, et al. Self-adjuvanting α-helical polypeptide simultaneously delivers neoantigen mRNAs and activates dendritic cells to eradicate tumors. Proceedings of the National Academy of Sciences. 2026;123(16). doi:10.1073/pnas.2504976123

BibTeX
@article{Han2026,
  author = {Han, Joonsu and Zhou, Jiadiao and Dwivedy, Abhisek and Xue, Tianrui and Bhatta, Rimsha and Liu, Yusheng and Nguyen, Daniel and Bo, Yang and Wang, Yueji and Wang, Xin and Xu, Meng and Berry, Matthew and Bailey, Keith and Irudayaraj, Joseph and Liu, Jian and Chen, Qian and Nie, Shuming and Wang, Xing and Wang, Hua},
  title = {Self-adjuvanting α-helical polypeptide simultaneously delivers neoantigen mRNAs and activates dendritic cells to eradicate tumors},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2026},
  volume = {123},
  number = {16},
  doi = {10.1073/pnas.2504976123}
}
Kostenlos starten →